Skip to main content

Table 1 Characteristics of manuscripts studied and outcome series extracted

From: Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer

  Manuscripts, N = 115 DLT series, N = 155 OR series, N = 93
Year of publication    
2008 13 (11%) 17 (11%) 13 (14%)
2009 9 (7.8%) 14 (9.0%) 10 (11%)
2010 9 (7.8%) 10 (6.5%) 8 (8.6%)
2011 20 (17%) 23 (15%) 11 (12%)
2012 26 (23%) 35 (23%) 23 (25%)
2013 16 (14%) 22 (14%) 16 (17%)
2014 22 (19%) 34 (22%) 12 (13%)
Experimental design    
Model-based 85 (74%) 116 (75%) 56 (60%)
Rule-based 30 (26%) 39 (25%) 37 (40%)
Disease class    
Non-haematological 82 (71%) 117 (75%) 71 (76%)
Haematological 30 (26%) 31 (20%) 18 (19%)
Both 2 (1.7%) 6 (3.9%) 4 (4.3%)
Not disclosed 1 (0.9%) 1 (0.6%) 0 (0%)
Disease    
Solid tumours   48 (31%) 29 (31%)
Breast cancer   9 (5.8%) 8 (8.6%)
Gastrointestinal cancer   10 (6.5%) 6 (6.5%)
AML   7 (4.5%) 6 (6.5%)
Lung cancer   9 (5.8%) 3 (3.2%)
Lymphoma   6 (3.9%) 5 (5.4%)
Multiple myeloma   6 (3.9%) 4 (4.3%)
Glioma   5 (3.2%) 4 (4.3%)
Melanoma   4 (2.6%) 4 (4.3%)
Mixed haematological cancers   8 (5.2%) 0 (0%)
CNS tumours   4 (2.6%) 3 (3.2%)
Head and neck cancer   4 (2.6%) 3 (3.2%)
Brain cancer   5 (3.2%) 1 (1.1%)
Lymphoma and advanced solid tumours   4 (2.6%) 2 (2.2%)
Sarcoma   3 (1.9%) 3 (3.2%)
CLL   3 (1.9%) 2 (2.2%)
Hepatocellular carcinoma   2 (1.3%) 2 (2.2%)
Renal cell carcinoma   2 (1.3%) 2 (2.2%)
Biliary tract cancer   3 (1.9%) 0 (0%)
Glioblastoma   2 (1.3%) 1 (1.1%)
NSCLC   2 (1.3%) 1 (1.1%)
SCLC   3 (1.9%) 0 (0%)
Cervical cancer   1 (0.6%) 1 (1.1%)